Cerebral lipid deposition in aged apolipoprotein-E-deficient mice

American Journal of Pathology

Volumn 151, Issue 5, 1997, Pages 1371-1377

  Walker, Lary C ^a   Parker, Carolyn A ^a   Lipinski, William J ^a   Callahan, Michael J ^a   Carroll, Richard T ^a   Gandy, Sam E ^b   Smith, Jonathan D ^c   Jucker, Mathias ^d   Bisgaier, Charles L ^a  

^a PFIZER INC   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGING; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL DIET; DIENCEPHALON; HYPERLIPOPROTEINEMIA TYPE 3; LIPID BRAIN LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER PARENCHYMA; MOUSE; NEOCORTEX; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; XANTHOMA;

AGING; ANIMALS; APOLIPOPROTEINS E; BRAIN; BRAIN DISEASES; CHOLESTEROL, DIETARY; DIETARY FATS; FEMALE; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; REFERENCE VALUES; XANTHOMATOSIS;

EID: 0030723548     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 140:622-630
2. Weisgraber KH, Pitas RE, Mahley RW: Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr Opin Struct Biol 1994, 4:507-515
3. Poirier J: Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994, 17:525-530
4. Boyles JK, Zoellner CD, Anderson U, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ, Shooter EM: A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989, 83:1015-1031
5. Rall SC Jr, Weisgraber KH, Mahley RW: Human apolipoprotein E: the complete amino acid sequence. J Biol Chem 1982, 257:4171-4178
6. Weisgraber KH, Rall SC Jr, Mahley RW: Human E apoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981, 256:4171-4178
7. Weisgraber KH: Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res 1990, 31:1503-1511
8. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21
9. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16:1250-1255
10. 4 and Alzheimer's disease. Arch Neurol 1995, 52:650
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923
12. Förstl H, Czech C, Sattel H, Geiger-Kabisch C, Besthorn C, Kreger S, Mönning U, Hartmann T, Masters C, Beyreuther K: Apolipoprotein E und Alzheimer-Demenz. Nervenarzt 1994, 65:780-785
13. Gomez-Isla T, West HL, Rebeck GW, Hart SD, Growdon JH, Locascio JJ, Perls TT, Lipsitt LA, Hyman BT: Clinical and pathological correlates of apolipoprotein Eε 4 in Alzheimer's disease. Ann Neurol 1996, 39:62-70
14. Kurz A, Lautenschlager N, Haupt M, Zimmer R, von Thülen B, Altland K, Lauter H, Müller U: Das Apolipoprotein E-ε4-Allel ist ein Risikofaktor für die Alzheimer-Krankheit mit frühem und spätem Beginn. Nervenarzt 1994, 65:774-779
15. Muramatsu T, Higuchi S, Arai H, Sasaki H, Yamada K, Hayashida M, Trojanowski JQ: Apolipoprotein E ε4 allele distribution in alcoholic dementia and in Alzheimer's disease in Japan. Ann Neurol 1994, 36:797-799
16. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699
17. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Jon SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E alleleε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472
18. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353
19. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N: Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992, 89:4471-4475
20. van Ree JH, Gijbels MJJ, van den Broek JAA, Hofker MH, Havekes LM: Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis 1995, 112:237-243
21. Breslow JL: Mouse models of atherosclerosis. Science 1996, 272: 685-688
22. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140
23. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK: Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994, 93:1885-1893
24. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD: Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995, 136:107-122
25. Genis I, Gordon I, Sehayek E, Michaelson DM: Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 1995, 199:5-8
26. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM: Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 1995, 199:1-4
27. Masliah E, Samuel W, Veinbergs I, Mallory M, Mante M, Saitoh T: Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res 1997, 751:307-314
28. Gandy S, Stafstrom C, Turner B, Sweeney D, Breslow J, Greengard P, Smith J, Ouimet C: Aged ApoE deficient mice: abnormal learning and glial markers but no obvious neuropathology. Soc Neurosci Abstr 1995, 21:5
29. Mercken L, Brion J-P: Phosphorylation of tau protein is not affected in mice lacking apolipoprotein E. NeuroReport 1995, 6:2381-2384
30. Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Walker LC: Effects of aging on glial and neural markers in apolipoprotein E-deficient mice. Soc Neurosci Abstr 1996, 22:207
31. Bodovitz S, Klein WL: Cholesterol modulates α-secretase cleavage of amyloid precursor protein. J Biol Chem 1996, 271:4436-4440
32. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR: Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94
33. Vercherre CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic β cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996, 93:3492-3496
34. Nishina PM, Verstuyft J, Paigen B: Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990, 31:859-869
35. Wolf A, Cowen D, Graham S: Xanthomas of the choroid plexus in man. J Neuropathol Exp Neurol 1950, 9:286-297
36. Ayres WW, Haymaker W: Xanthoma and cholesterol granuloma of the choroid plexus. J Neuropathol Exp Neurol 1960, 19:280-295
37. Jaer Ø, Løken AC, Nesbakken R: Hydrocephalus due to xanthogranuloma. J Neurosurg 1973, 39:659-661
38. Hicks MJ, Albrecht S, Trask T, Byrne ME, Narayan RK, Goodman JC: Symptomatic choroid plexus xanthogranuloma of the lateral ventricle. Clin Neuropathol 1993, 12:92-96
39. Hammond RR, Mackenzie IRA: Xanthoma disseminatum with massive intracranial involvement. Clin Neuropathol 1995, 14:314-321
40. Stewart MJ: Xanthoma and xanthosis. Br Med J 1924, 2:893-896
41. Beeson BB, Albrecht PG: A contribution to the study of xanthoma tuberosum, with report of a case. Arch Dermatol Syph 1923, 8:695-710
42. Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K. Tanaka N: Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci 1993, 114:227-230
43. Cali JJ, Hsieh CL, Francke U, Russell DW: Mutations in the bile acid biosynthesis enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991, 266:7779-7783
44. Polano MK: Xanthoma types in relation to the type of hyperlipoproteinemia. Nutr Metab 1973, 15:107-118
45. Algoed L, Caemaert J, Achten E, van Aken J, de Reuck J: A large intracranial xanthoma in familial hypercholesterolemia. Clin Neurol Neurosurg 1994, 96:79-82
46. Mann GV, Andrus SB: Xanthomatosis and atherosclerosis produced by diet in an adult rhesus monkey. J Lab Clin Med 1956, 48:533-550
47. Belza J, Rubinstein LJ: Experimental cerebral atherosclerosis in dogs. Ann NY Acad Sci 1968, 149:895-906
48. Altschul R: Experimental arteriosclerosis in the nervous system. J Neuropathol Exp Neurol 1946, 5:333-341
49. Greenberg SM, Rebeck GW, Vonsattel J-PG, Gomez-Isla T, Hyman BT: Apolipoprotein Eε 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995, 38:254-259
50. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE: Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 1995, 92:3586-3590
51. Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, März W: Apolipoprotein E polymorphism influences not only cerebral plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995, 66:583-587
52. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinistö L, Halonen P, Kontula K: Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995, 333:1242-1247
53. Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN: Apolipoprotein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996, 148:2083-2095
54. Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580
55. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:9649-9653
56. Walker LC, Warzok R, Dünnewald S, Apel G, Schwarz A, Egensperger R, Schreiber D, Troncoso JC, Kessler C: Apolipoprotein Eε4 promotes early β-amyloid deposition in the nondemented elderly. Soc Neurosci Abstr 1996, 22:1696
57. Warzok RW, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, Herbst EW, Wolf E, Walther R, Walker LC: Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord (in press)
58. Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD: Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995, 69:757-761
59. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala E-L, Partanen K, Ryynänen M, Vaino P, Hartikainen P, Riekkinen PJ Sr: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995, 67:65-72
60. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996, 334:752-758
61. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997, 349:151-154
62. Slooter AJC, Tang M-X, van Duijn CM, Stern Y, Ott A, Bell K, Breteler MMB, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A, Mayeux R: Apolipoprotein E ε4 and the risk of dementia with stroke. J Am Med Assoc 1997, 277:818-821
63. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. J Am Med Assoc 1997, 277:813-817
64. Grant WB: Dietary links to Alzheimer's disease. Alzheimer's Dis Rev 1997, 2:42-55
65. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radical Biol Med 1996, 20:707-727
66. Daugherty A, Roselaar SE: Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995, 29:297-311
67. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1792
68. Smith MA, Sayre L, Perry G: Is Alzheimer's a disease of oxidative stress? Alzheimer's Dis Rev 1996, 1:63-67
69. Montine KS, Olson SJ, Amamath V, Whetsell WO Jr, Graham DG, Montine TJ: Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 1997, 150:437-443
70. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997, 17:2653-2657
71. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997, 68:2092-2097
72. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity, and effects on cytotoxicity by oxidative insults, and β-amyloid peptides: Nature Genet 1996, 14:55-61